Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) is a biotechnology company specializing in regenerative medicine. The company uses placental cells and a unique proprietary three-dimensional (3D) technology platform to develop cell therapies for conditions such as inflammation, muscle injuries, hematological disorders, and exposure to radiation.

Partner's Genome Editing vision​

Pluristem aims to bring its allogeneic cell therapy and manufacturing expertise to the CRISPR-IL consortium, and to lead the development of next-generation allogeneic cell therapies to treat the diseases of today and of the future.

Partner's activity within the consortium

Pluristem leads the biopharma workgroup in the consortium, and contributes gene editing data from experiments on Placental eXpanded (PLX) cells.